Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koltun

Showing results (411-420 of 423) with videos related to

Pageof 43
Sort By:
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)Kenneth D Rice, Naing Aay, Neel K Anand, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2012
The design, synthesis, and biological evaluation of PIM kinase inhibitorsAmy Lew Tsuhako, David S Brown, Elena S Koltun, et al.
Journal of Medicinal Chemistry|June 24, 2011
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potentialJose M Coteron, María Marco, Jorge Esquivias, et al.
Diseases of the Colon and Rectum|November 1, 2005
Practice parameters for the surgical treatment of ulcerative colitisJeffrey L Cohen, Scott A Strong, Neil H Hyman, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2012
Discovery of XL413, a potent and selective CDC7 inhibitorElena S Koltun, Amy Lew Tsuhako, David S Brown, et al.
Science (New York, N.Y.)|August 17, 2023
Chemical remodeling of a cellular chaperone to target the active state of mutant KRASChristopher J Schulze, Kyle J Seamon, Yulei Zhao, et al.
Journal of Medicinal Chemistry|October 4, 2016
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I<sub>Na</sub>i), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic PropertiesJeff A Zablocki, Elfatih Elzein, Xiaofen Li, et al.
Science (New York, N.Y.)|July 24, 2025
A neomorphic protein interface catalyzes covalent inhibition of RAS<sup>G12D</sup> aspartic acid in tumorsCaroline Weller, G Leslie Burnett, Lingyan Jiang, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Pageof 43

Showing results (411-420 of 423) with videos related to

Sort By:
Pageof 43
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)Kenneth D Rice, Naing Aay, Neel K Anand, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2012
The design, synthesis, and biological evaluation of PIM kinase inhibitorsAmy Lew Tsuhako, David S Brown, Elena S Koltun, et al.
Journal of Medicinal Chemistry|June 24, 2011
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potentialJose M Coteron, María Marco, Jorge Esquivias, et al.
Diseases of the Colon and Rectum|November 1, 2005
Practice parameters for the surgical treatment of ulcerative colitisJeffrey L Cohen, Scott A Strong, Neil H Hyman, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2012
Discovery of XL413, a potent and selective CDC7 inhibitorElena S Koltun, Amy Lew Tsuhako, David S Brown, et al.
Science (New York, N.Y.)|August 17, 2023
Chemical remodeling of a cellular chaperone to target the active state of mutant KRASChristopher J Schulze, Kyle J Seamon, Yulei Zhao, et al.
Journal of Medicinal Chemistry|October 4, 2016
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I<sub>Na</sub>i), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic PropertiesJeff A Zablocki, Elfatih Elzein, Xiaofen Li, et al.
Science (New York, N.Y.)|July 24, 2025
A neomorphic protein interface catalyzes covalent inhibition of RAS<sup>G12D</sup> aspartic acid in tumorsCaroline Weller, G Leslie Burnett, Lingyan Jiang, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Pageof 43